Vir Biotechnology (VIR) Total Liabilities (2018 - 2026)

Vir Biotechnology has disclosed Total Liabilities across 9 years of filings, most recently posting $212.8 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $212.8 million, down 19.36% year-over-year; the trailing twelve-month figure through Mar 2026 was $212.8 million (down 19.36% YoY), and the FY2025 annual result was $237.5 million, down 4.38% from the prior year.
• Total Liabilities came in at $212.8 million for Q1 2026 at Vir Biotechnology, down from $237.5 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $886.1 million in Q1 2022 to a low of $212.8 million in Q1 2026.
• The 5-year median for Total Liabilities is $263.9 million (2025), against an average of $401.3 million.
• Across the five-year window, Total Liabilities jumped 108.27% in 2022 and plunged 64.52% in 2024, its largest moves.
• Vir Biotechnology's Total Liabilities stood at $724.1 million in 2022, then slumped by 54.59% to $328.8 million in 2023, then retreated by 24.45% to $248.4 million in 2024, then slipped by 4.38% to $237.5 million in 2025, then decreased by 10.41% to $212.8 million in 2026.
• The last three Total Liabilities figures came in at $212.8 million (Q1 2026), $237.5 million (Q4 2025), and $223.4 million (Q3 2025), per Business Quant data.